Ito Yasuhiro, Miyauchi Akira, Masuoka Hiroo, Fukushima Mitsuhiro, Kihara Minoru, Miya Akihiro
Department of Surgery, Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, Hyogo, 650-0011, Japan.
World J Surg. 2018 Aug;42(8):2462-2468. doi: 10.1007/s00268-018-4497-x.
In Japan, prophylactic central node dissection (p-CND) for papillary thyroid carcinoma (PTC) has been routinely performed in many institutions, including ours (Kuma Hospital, Japan). We evaluated the recurrence to a central lymph node in patients with cN0M0 PTC who underwent routine p-CND.
We enrolled 4301 patients with cN0M0 PTC who underwent an initial surgery between 1987 and 2005 (median age 51 years). The postoperative follow-up periods ranged from 4 to 362 months (median 164 months). Only 15 patients underwent radioactive iodine (RAI) ablation (≥30 mCi) after total or near total thyroidectomy.
Of the 4301 patients with N0M0 PTC who underwent p-CND, 2548 (59%) were diagnosed as pN1a on postoperative pathological examination. To date, only 52 cases (1.2%) showed recurrence to a central lymph node. The 10-year and 20-year central node recurrence-free survival rates were excellent at 99.1 and 98.2%, respectively. On multivariate analysis, age ≥55 years, significant extrathyroid extension, tumor size >2 cm, and ≥5 pathologically confirmed central node metastases (but not the presence of central node metastasis) independently affected central node recurrence.
Under the situation of routine p-CND, the central node recurrence-free survival of cN0M0 PTC is excellent. However, future studies, including double-arm studies from Japan, should examine whether the omission of p-CND cN0M0 PTC is appropriate without RAI ablation in consideration of various factors, including the pros and cons of p-CND.
在日本,包括我们医院(日本久留米医院)在内的许多机构都对甲状腺乳头状癌(PTC)常规进行预防性中央区淋巴结清扫术(p-CND)。我们评估了接受常规p-CND的cN0M0 PTC患者中央区淋巴结的复发情况。
我们纳入了1987年至2005年间接受初次手术的4301例cN0M0 PTC患者(中位年龄51岁)。术后随访时间为4至362个月(中位164个月)。仅15例患者在全甲状腺切除或近全甲状腺切除术后接受了放射性碘(RAI)消融(≥30 mCi)。
在4301例接受p-CND的N0M0 PTC患者中,2548例(59%)术后病理检查诊断为pN1a。迄今为止,仅52例(1.2%)出现中央区淋巴结复发。10年和20年中央区淋巴结无复发生存率分别高达99.1%和98.2%。多因素分析显示,年龄≥55岁、明显的甲状腺外侵犯、肿瘤大小>2 cm以及≥5个经病理证实的中央区淋巴结转移(而非中央区淋巴结转移的存在)独立影响中央区淋巴结复发。
在常规p-CND的情况下,cN0M0 PTC的中央区淋巴结无复发生存情况良好。然而,未来的研究,包括来自日本的双臂研究,应考虑p-CND利弊等各种因素,探讨在不进行RAI消融的情况下,省略cN0M0 PTC的p-CND是否合适。